The 2026 American Association for Cancer Research annual meeting in San Diego stands as a definitive proving ground where South Korean biotechnology firms must transition from theoretical promise to clinical validation. Unlike later-stage conferences such as ASCO or ESMO, the AACR provides a unique
For a patient navigating the harrowing landscape of a cancer diagnosis, the difference between survival and a terminal prognosis often hinges on the proximity of their residence to cutting-edge medical research facilities. Despite significant breakthroughs in precision oncology and immunotherapy, a
The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,
Ivan Kairatov is a leading biopharma expert specializing in the intersection of biotechnology and clinical innovation. With extensive experience in research and development, he has spent his career bridging the gap between laboratory breakthroughs and practical healthcare solutions. In this
Groundbreaking research involving more than twenty thousand oncology patients has finally pulled back the curtain on a quiet crisis where medical treatments are inadvertently failing to account for the fundamental biological differences between men and women. For decades, the medical community
The relentless physical and psychological burden of chronic cholestatic pruritus often defines the daily existence of patients long before a clinical diagnosis is even finalized. For those living with rare liver diseases, the sensation of an internal, unreachable itch is not merely a symptom but a
